trial

Boost rTMS for Auditory Verbal Hallucinations

NCTId NCT03544333
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 5 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2019-01-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
5 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-04-16
Primary completion
2019-01-22
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Transcranial Magnetic Stimulation

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor

Investigators

1
Philipp Homan, MD PhDPrincipal Investigator

Sites

1 total
Manhasset, United States

Facts & assertions

4 sourced
Enrollment
5
Phase
NA
Primary Completion Date
2019-01-22
Status
TERMINATED
relationships
The graph out of here
drug
Transcranial Magnetic Stimulation
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
indication
Schizophrenia
indication
Hallucinations
indication
Schizophrenia
indication
investigator
Philipp Homan, MD PhD
person